Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WBRT and SRS With or Without Temozolomide or Erlotinib in NSCLC Brain Metastases
NCT00096265Phase 3Terminated
- Sponsor
- National Cancer Institute
- Start
- Oct 2004
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of temozolomide, erlotinib in non-small cell lung cancer (NSCLC), brain metastases, sponsored by National Cancer Institute. Started Oct 2004; status: terminated.
02
Drugs
temozolomideerlotinib
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on NCT00096265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00096265.